CatalYm GmbH: CatalYm Starts First-in-Human Phase I Clinical Trial with GDF-15 Neutralizing Antibody CTL-002 to Treat Patients with Checkpoint-Inhibitor Refractory Cancer

Written by Petra Hegmann on 28th January 2021. Posted in Client News.

• Previous
• Next